-
Bone Therapeutics has partnered with Implant Therapeutics to gain access to iPSC derived, genetically engineered MSCs. These
-
Bone Therapeutics will gain access to iPS cell lines, including hypoimmunogenic cell lines, differentiation protocols and expertise
Press Releases (Sponsored)
Press releases may be paid content. The issuer is solely responsbile for its content.
BioInformant's coverage of stem cell news includes iPS cells, MSCs, hematopoietic stem cells, and beyond.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal and Vogue Magazine, as well as cited in Tony Robbins' best-selling book, Life Force.
Therapeutic Solutions Utilizes MSC Exosomes to Suppress Inflammatory Pathologies
-
Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production
-
Patent Filed on Potential Solution to Cause of Major Inflammatory Pathologies
ELK CITY, Idaho, Oct. 4, 2021 — Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced laboratory data demonstrating that exosomes produced by JadiCells™, the Company’s Phase III cell therapy candidate for COVID-19 and other lung pathology, as well as mesenchymal stem cells proprietary to the Company, can suppress the production of neutrophil extracellular traps. [Read more…]
Koji Tanabe, CEO of I Peace, Inc. honored by World Biz Magazine with “Top 100 Innovation CEO” Award
September 21, 2021, Palo Alto, California – Koji Tanabe, Founder and CEO of I Peace, Inc., has been selected by the judges of World Biz Magazine’s annual awards to be a recipient of the “Top 100 Innovation CEO – 2021”. [Read more…]
Bio-Techne Launches ExCellerate™ iPSC Expansion Medium
A novel animal component-free medium that supports robust expansion and maintenance of human pluripotent stem cells.
Minneapolis, September 14, 2021 — Bio-Techne Corporation (NASDAQ: TECH) Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells (iPSCs) for use in both research and translational workflows. The ExCellerate™ iPSC Expansion Medium is the latest addition to Bio-Techne’s comprehensive portfolio of products and services for Regenerative Medicine. It is designed to fit seamlessly into their offerings for stem cell workflows, including cell isolation, reprogramming, genome engineering, cell expansion, differentiation and characterization. [Read more…]
JW Therapeutics Achieves Approval of Sixth CAR-T Product Globally by NMPA in China
-
The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally
-
Currently the only approved CAR-T product that has been simultaneously included in the National Significant New Drug Development Program, granted priority review and breakthrough therapy designation
-
May provide a best-in-class CAR-T therapy in China given its demonstration of high rates of durable disease response and low rates of CAR-T associated toxicities
- « Previous Page
- 1
- …
- 77
- 78
- 79
- 80
- 81
- …
- 145
- Next Page »